Regulatory approval for Elekta's acquisition of Nucletron

Regulatory approval for Elekta's acquisition of Nucletron

Press Release
Stockholm, Sweden, September 13, 2011

The Elekta group will provide improved value for cancer patients and
health care providers, by addressing a broader range of cancers, in
different body sites, and across a broader range of disease stages.

Elekta AB (publ) today announced it has obtained the required regulatory
approval for its acquisition of Nucletron, the world leader in
brachytherapy treatment planning and delivery. The closing of the
transaction is expected in the coming days.

Through the combination Elekta will offer a complete range of
radiotherapy planning and delivery technologies. As market leader in
Europe and with strong positions in North America and Asia, Elekta will
enhance the combined ability to meet the clinical needs of cancer
patients and health care providers throughout the world.

Nucletron will be integrated into Elekta's organization and assume the
responsibility as a center of excellence in the development of
brachytherapy solutions, becoming the fourth Business Area at Elekta -
alongside Oncology, Neuroscience and Software.

“Now we have received the go-ahead to conclude the deal, and we are very
enthusiastic about building a broader, stronger and highly complementary
range of cutting-edge cancer care solutions,” said Elekta President and
CEO Tomas Puusepp. “Elekta is committed to brachytherapy and to continue
the ongoing development. I welcome our new colleagues to work with us on
a best practice basis in the interest of enhancing patient and customer
value by providing solutions that improve, prolong and save lives.”

“By joining the Elekta Group we will have a much stronger ability to
pioneer cutting-edge cancer care through shared know-how and R&D
capabilities,” said Nucletron CEO Jos Lamers. “This combination
represents a unique opportunity to realize the true potential of
Nucletron and Elekta by extending our combined geographic reach and
distribution capacity. During the coming integration period we will work
hard together to fully exploit our joint potential to serve patients.“

Nucletron will add approximately 1,000 new customers to Elekta's
customer base of more than 5,000 and the combination will allow the
enlarged group to take mutual advantage of Nucletron's expertise in
brachytherapy combined with Elekta's global presence, particularly in
emerging markets.

Under the terms of the acquisition agreement of June 21, 2011, Elekta is
paying a cash consideration of EUR 365 million to acquire Nucletron on a
cash and debt-free basis. The acquisition is expected to be accretive to
Elekta's cash earnings within twelve months. The transaction is financed
through existing cash on hand and available credit facilities.

***

For further information, please contact:
Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37, email:
stina.thorman@elekta.com (stina.thorman@elekta.com)

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial
Instruments Trading Act. The information was published at 15.00 CET on
September 13, 2011. 

About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The company
develops sophisticated, state-of-the-art tools and treatment planning
systems for radiation therapy and radiosurgery, as well as workflow
enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing
intelligent and resource-efficient solutions that offer confidence to
both healthcare providers and patients, Elekta aims to improve, prolong
and even save patient lives, making the future possible today.
 
Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive
diagnosis, treatment or follow-up with the help of a solution from the
Elekta Group. Elekta reported net sales of SEK 7,904 M and EBITDA of SEK
1,744 M. Elekta employs around 2,800 employees globally. The corporate
headquarter is located in Stockholm, Sweden, and the company is listed
on the Nordic Exchange under the ticker Elekta. Website:
www.elekta.com (http://www.elekta.com/)

About Nucletron
Nucletron provides state of the art radiotherapy solutions for cancer
treatment that meet the evolving needs of patients, their caregivers and
healthcare professionals around the world. Nucletron has unmatched
global leadership in brachytherapy, a very precise, highly effective and
well-tolerated treatment option for healthcare providers, tailored to
the needs of individual patients.

The company works with clinical teams to constantly improve and develop
an innovative portfolio of integrated products, software and services
that assures excellent patient outcomes. Headquartered in Veenendaal,
The Netherlands, Nucletron employs more than 500 employees, with offices
in 18 countries, and products available in more than 100 countries
around the world. Website: www.nucletron.com